BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% ...

MetaVia has shared an update on its attempt to crash the obesity party, reporting average weight loss of 9.1% in people who ...

Ascletis Pharma has received investigational new drug (IND) clearance from the US Food and Drug Administration (FDA) to begin ...

Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced that the first patient has been ...

"MetaVia OXM analogue agonist meets endpoints in Phase Ib weight loss trial" was originally created and published by Clinical ...

Panelists discuss how clinicians are beginning to integrate xanomeline/trospium into practice for patients who have struggled ...

The trial had 24 patients, exceeding the original target of 20, and included a 4-week baseline. ・In the Absence cohort, ...

Designing STEM classrooms that encourage students to reflect on their progress and share their stories takes intention, but ...

Safety in pediatric sedation relies on strict guidelines and monitoring, so let's learn how providers utilize pharmacological ...

MetaVia Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced positive statistically significant results from the 8-week (extended from four ...

New guidelines for blood-based biomarkers, the impact of hormone replacement therapy and risks for cognitive decline with red ...